clinical trial · NCT06298630
Long-term Follow-up Study of BRL-101 for TDT
Bioray Laboratories·—·not yet recruiting·n = 45
Thalassemia, BetaAssessments
brief summary
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
started
Dec 8, 2024
primary completion
Aug 20, 2038
completion
Oct 15, 2038
last updated
Mar 22, 2024
detailed description
Observe long-term delayed safety risks such as emerging neoplasms, emerging haematological disorders, and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
official title
Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol